Mannan-binding lectin (MBL) was first discovered as a plasma opsonin for baker's yeast and was independently characterized biochemically. It belongs to the small subfamily of collectins: C-type lectins possessing a collagen-like domain. MBL is synthesized by the liver and secreted into the bloodstream. It is believed to be an important component of innate immunity, acting as an ante-antibody and/or as a disease modifier. It is thought to influence disorders as diverse as meningococcal disease, rheumatoid arthritis, cystic fibrosis and recurrent miscarriage. Lack of MBL may be most relevant in the context of a co-existing secondary immune deficiency. Replacement therapy, first carried out 30 years ago with unfractionated plasma, appears promising. The development of a recombinant product should permit the extension of MBL therapy to randomized clinical trials of sufficient size to provide clear evidence about the physiological significance of this intriguing glycoprotein.
Skip Nav Destination
- PDF Icon PDF LinkFront Matter
Conference Article| August 01 2003
Introduction to mannan-binding lectin
D.C. Kilpatrick 1
Scottish National Blood Transfusion Service National Science Laboratory, Ellen's Glen Road, Edinburgh EH17 7QT, U.K.
Search for other works by this author on:
Biochem Soc Trans (2003) 31 (4): 745–747.
D.C. Kilpatrick; Introduction to mannan-binding lectin. Biochem Soc Trans 1 August 2003; 31 (4): 745–747. doi: https://doi.org/10.1042/bst0310745
Download citation file:
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your InstitutionSign in via your Institution
Get Access To This Article
Buy This Article